Phase III VISION trial showed Pluvicto plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 Approximately 473,000 prostate cancer cases and
PARIS (AFP) – The progression of certain types of breast cancers can be slowed by identifying a particular genetic mutation and then quickly adapting treatment, a first-of-its-kind study showed on Friday. Breast cancer tumour cells change over time, and sometimes cause mutations that are resistant to the drugs the patients are taking. For the new […]
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian cancer
Vaborem, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in ChinaThe deal brings
Tumour cells are infamous for their ability to evade the human immune system; they construct physical barriers, disguise themselves, and handcuff the immune sys